






OPEN ACCESS

Prevalence and genetic–phenotypic characteristics of patients with *USH2A* mutations in a large cohort of Chinese patients with inherited retinal disease

Feng-Juan Gao ^{1,2,3}, Dan-Dan Wang,^{1,2,3} Fang Chen,^{4,5,6} Hao-Xiang Sun,⁷ Fang-Yuan Hu,^{1,2,3} Ping Xu,^{1,2,3} Jiankang Li,^{6,8} Wei Liu ^{1,2,3}, Yu-He Qi,^{1,2,3} Wei Li,^{6,9} Ming Wang,^{1,2,3} Shenghai Zhang,^{1,2,3} Ge-Zhi Xu,^{1,2,3} Qing Chang ^{1,2,3}, Ji-Hong Wu^{1,2,3}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bjophthalmol-2020-315878>).

For numbered affiliations see end of article.

Correspondence to

Professor Ji-Hong Wu, Ophthalmology, Shanghai, China; jihongwu@fudan.edu.cn

QC and J-HW contributed equally.

F-JG, D-DW and FC are joint first authors.

Received 15 January 2020
Revised 27 February 2020
Accepted 29 February 2020
Published Online First
18 March 2020

ABSTRACT

Aims To investigate the frequency of *USH2A* mutation and the clinical and genetic differences between Usher syndrome type II (USH2) and retinitis pigmentosa (RP) in a large cohort of Chinese patients.

Methods A total of 1381 patients with inherited retinal disease (IRD) were recruited. The phenotypic and genotypic information of patients with *USH2A* mutations was evaluated.

Results The prevalence of patients with *USH2A* mutations was 15.75%, which was the most frequently detected gene in this cohort of patients. Hotspot of *USH2A* mutations was c.8559-2A>G and c.2802T>G. Patients with USH2 had an earlier and more serious decline of visual function and damage to retina structure than did patients with RP in the first 10 years ($p<0.05$), but there was no difference in the visual prognosis between the two groups when the course of disease exceeded 10 years ($p>0.05$). Missense variants had less severe consequences and were found more commonly in RP, whereas more deleterious genotypes were associated with an earlier onset of disease and were found more commonly in USH2.

Conclusions This study provides detailed clinical–genetic assessment of patients with *USH2A* mutations of Chinese origin, enabling precise genetic diagnoses, better management of these patients and putative therapeutic approaches.

INTRODUCTION

The *USH2A* gene (OMIM #608400), located on chromosome 1q41, consists of 72 exons, and encodes usherin, a transmembrane protein present in the basement membrane of many, but not all, tissues, including the photoreceptor layer of the retina and the hair cells in the cochlea. Usherin is important in the development and homeostasis of the inner ear and retina. Different mutations within this gene have been associated with a large heterogeneous group of diseases, including retinitis pigmentosa (RP), Usher syndrome type II (USH2), cone-rod dystrophy and deafness.^{1,2} The different phenotypes associated with *USH2A* are thought to be due to an allelic hierarchy of *USH2A* mutations.³

To date, many efforts have been made to investigate the spectrum of mutations and genotype–phenotype correlations in patients with *USH2A*

mutations. More than 1100 disease-causing variants in *USH2A* have been identified, including nonsense and missense mutations, splicing variants, small deletions and insertions, small indels and large rearrangements (Human Gene Mutation Database; professional version 2019.3). Previous studies confirmed that two truncating mutations in *USH2A* were associated mostly with USH2 in patients from Netherlands and Belgium, whereas other combinations can result in both RP and USH2.⁴ Moreover, the presence of at least one truncating mutation was associated with earlier presentation of visual decline. However, the mutation frequency and genotype–phenotypic characteristics vary widely between different ethnic groups.^{5,6} For example, the most frequent mutations in *USH2A* were the p.Glu767Serfs*21 and p.Cys759Phe mutations in Madrid,⁷ p.Glu767Serfs*21 of USH2 cases in Europe,⁸ p.Cys759Phe in RP cases in Spanish patients.⁹ Previous research found that p.Glu767Serfs*21 was associated mainly with USH2¹⁰ and p.Cys759Phe with RP; however, Blanco-Kelly *et al* revealed that more than 60% of patients with p.Cys759Phe and 72.1% of patients with p.Glu767Serfs*21 had mild hearing loss.⁷

The genetic and clinical characteristics of patients with *USH2A* mutations have been reported in many studies; however, data for Chinese patients are limited. The exact genetic and phenotypic characteristics of patients with *USH2A* mutations in Chinese patients with inherited retinal disease (IRD) remain unknown. In the present study, we enrolled 1381 patients with IRD; patients underwent molecular analysis and all those with *USH2A* mutations were identified. Our aim was to investigate the genotype–phenotypic characteristics and differences between RP and USH2 in a large series of patients with *USH2A* mutations in the Chinese population. These results would be useful for prognosis, clinical management and genetic counselling and should provide strong evidence-based data support for gene therapy studies.

METHODS

Subjects and ethical statement

This study was approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University and adhered to the tenets of the Declaration of



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Gao F-J, Wang D-D, Chen F, *et al*. *Br J Ophthalmol* 2021;**105**:87–92.

Helsinki. A total of 1381 patients with IRD and their available family members (total participants: 3967) were recruited from our genetics department between January 2016 and June 2019. Written informed consent was obtained from all participants before peripheral blood samples were collected.

Next-generation sequencing analysis

Molecular testing was performed by targeted next-generation sequencing as previously reported.⁶ After sequencing, data analysis was performed as reported previously.^{6–11} Previously reported variants were determined using ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and Human Gene Mutation Database (professional 2019.3). The potential pathogenicity of the variants was interpreted according to the American College of Medical Genetics. Before confirmation by Sanger sequencing, the candidate variants were reviewed by clinical geneticists and ophthalmologists. Segregation analysis was performed within family members.

Clinical examination

Full ophthalmic examinations were performed on all patients with pathogenic mutations in *USH2A*, including the best Snellen-corrected visual acuity testing (BCVA), slit lamp biomicroscopy, fundus examination, visual field (VF, Humphrey Visual Field Analyzer, Carl Zeiss, Dublin, California, USA), swept-domain optical coherence tomography (Spectralis HRA +OCT, Heidelberg Engineering, Heidelberg, Germany) and

full-field electroretinography (according to the standards of the International Society for Clinical Electrophysiology of Vision; www.iscev.org). VF was assessed by 30-2 Swedish Interactive Threshold Algorithm Fast Programs to measure 30° temporally and nasally and test 76 points. The VF data were excluded if fixation miss loss and false-positive and false-negative response rates were greater than 20%. Average depression of visual sensitivity was estimated by mean deviation (MD). The central foveal thickness (CFT, within the central 1 mm region) was defined as the distance between the internal limiting membrane and the inner border of the retinal pigment epithelium. To provide numeric values for low BCVAs, the following conversions were made: no light perception, 0; light perception, 0.0001; hand movements, 0.001; and counting fingers, 0.01. Clinical diagnosis of USH2 and RP was based on ocular examination and hearing tests. Patients with USH2 have typical RP fundus appearance, sensorineural hearing impairment and intact vestibular function, and RP referred to non-syndromic RP, which has typical RP fundus appearance without extraocular disorders in this study.

Statistical analysis

Measurement values of the groups were compared using the t-test and one-way analysis of variance test. Correlations were evaluated using the Pearson and partial correlation tests. Statistical analyses were performed using SPSS V.20.0 (SPSS/IBM Corp.) and Microsoft Excel (2010). $P < 0.05$ was considered statistically significant.

Table 1 Distribution of clinical characteristics in patients with *USH2A* mutations

Characteristic	RP (n=75)	USH2 (n=88)	P value (t-test)
Female/male	35/40	35/53	0.374
Mean age \pm SD (range), years	45.85 \pm 14.96 (2–78)	40.21 \pm 15.32 (6–80)	0.647
Mean onset age \pm SD (range), years	23.37 \pm 15.72 (0–64)	15.34 \pm 12.62 (0–46)	0.01
Mean BCVA \pm SD (range)	0.35 \pm 0.30 (0.0001–1)	0.38 \pm 0.32 (0.0001–1)	0.495
Age, \leq 50 years	0.43 \pm 0.30*	0.46 \pm 0.31*	0.499
Age, >50 years	0.22 \pm 0.257	0.11 \pm 0.22	<0.05 (0.033)
Duration, \leq 10 years	0.54 \pm 0.30†	0.56 \pm 0.29†	0.755
Duration, 10–20 years	0.44 \pm 0.26	0.47 \pm 0.36	0.705
Duration, >20 years	0.24 \pm 0.27	0.25 \pm 0.25	0.856
Mean duration \pm SD (range), years	23.27 \pm 16.13 (3–78)	24.50 \pm 15.25 (2–70)	0.651
Mean MD \pm SD (range), dB	–25.06 \pm 6.06 (–33.60 to –4.24)	–26.11 \pm 4.67 (–33.25 to –9.6)	0.362
Age, \leq 50 years	–23.73 \pm 6.45*	–26.59 \pm 3.61	<0.01 (0.007)
Age, >50 years	–27.67 \pm 3.27	–27.29 \pm 7.46	0.835
Duration, \leq 10 years	–20.71 \pm 7.45†	–26.26 \pm 3.28	<0.01 (0.006)
Duration, 10–20 years	–25.55 \pm 3.95	–25.65 \pm 4.78	0.968
Duration, >20 years	–27.42 \pm 3.95	–27.34 \pm 4.61	0.910
Mean CFT (μ m)	223.78 \pm 55.46	210.28 \pm 39.31	0.132
Age, \leq 50 years	232.39 \pm 49.93*	210.75 \pm 39.63	<0.05 (0.015)
Age, >50 years	204.53 \pm 43.62	203.25 \pm 39.66	0.761
Duration, \leq 10 years	256.67 \pm 52.76§	224.00 \pm 33.03	<0.05 (0.04)
Duration, 10–20 years	223.71 \pm 38.70	206.05 \pm 44.63	0.116
Duration, >20 years	220.95 \pm 51.83	204.60 \pm 35.07	0.268

*Best Snellen corrected visual acuity (BCVA), visual field (VF) and central foveal thickness (CFT) of patients younger than 50 years old had significant differences with that of patients older than 50 years ($p < 0.001$, $p < 0.01$, $p < 0.05$).

†BCVA of patients with duration \leq 10 years was better than that of patients with duration >20 years ($p < 0.001$) but there was no difference from patients with duration 10–20 years ($p = 0.079$).

‡VF of patients with duration \leq 10 years was better than that of patients with duration >10 years ($p < 0.05$), but there was no difference in mean deviation (MD) between patients with retinitis pigmentosa (RP) with duration 10–20 years and >20 years ($p > 0.05$).

§CFT of patients with duration \leq 10 years was thicker than that of patients with duration >10 years ($p < 0.05$), but there was no difference in CFT between patients with RP with duration 10–20 years and >20 years ($p > 0.05$).

BCVA, best Snellen corrected visual acuity; CFT, center foveal thickness; MD, mean deviation; RP, retinitis pigmentosa; SD, standard deviation; USH2, Usher syndrome type IIa.

Table 2 Correlations of best Snellen corrected visual acuity (BCVA), mean deviation (MD) and center foveal thickness (CFT) with age and disease duration in patients with *USH2A* mutations

	BCVA		MD		CFT	
	R value	P value	R value	P value	R value	P value
Age*	-0.323	<0.001	-0.015	0.434	-0.199	0.023
RP	-0.207	0.016	-0.149	0.129	-0.312	0.018
Ages						
≤50, years	-0.032	0.397	-0.294	0.035	-0.095	0.308
>50, years	-0.290	0.041	-0.605	0.003	-0.209	0.236
Durations						
≤10 years	-0.032	0.438	-0.120	0.312	-0.087	0.418
10–20 years	-0.433	0.041	-0.590	0.082	-0.688	0.003
>20 years	-0.285	0.013	-0.104	0.290	-0.437	0.024
USH2	-0.431	<0.001	-0.357	0.002	-0.182	0.092
Ages						
≤50	-0.277	0.003	-0.132	0.172	-0.228	0.062
>50	-0.387	0.019	-0.803	0.005	-0.246	0.297
Durations						
≤10 years	-0.376	0.032	-0.085	0.381	-0.542	0.028
10–20 years	-0.401	0.010	-0.471	0.052	-0.318	0.08
>20 years	-0.490	<0.001	-0.456	0.004	-0.527	0.01
Duration†	-0.182	0.002	-0.250	0.003	-0.036	0.362
RP	-0.272	0.002	-0.451	<0.001	-0.078	0.306
Ages						
≤50, years	-0.405	<0.001	-0.406	0.005	-0.007	0.485
>50, years	-0.030	0.431	-0.317	0.093	-0.147	0.308
Durations						
≤10 years	-0.105	0.301	-0.364	0.063	-0.377	0.179
10–20 years	-0.374	0.070	-0.867	0.006	-0.363	0.101
>20 years	-0.080	0.270	-0.088	0.319	-0.475	0.015
USH2	-0.062	0.243	-0.107	0.202	-0.007	0.480
Ages						
≤50, years	-0.038	0.353	-0.096	0.247	-0.056	0.353
>50, years	-0.146	0.225	-0.177	0.324	-0.288	0.265
Durations						
≤10 years	-0.357	0.040	-0.200	0.238	-0.663	0.007
10–20 years	-0.183	0.154	-0.392	0.092	-0.171	0.229
>20 years	-0.227	0.031	-0.211	0.119	-0.371	0.059

*Corrected for the time of disease duration.

†Corrected for age.

BCVA, best Snellen corrected visual acuity; CFT, center foveal thickness; MD, mean deviation; RP, retinitis pigmentosa; USH2, Usher syndrome type IIa.

RESULTS

Cohort characteristics

Of the 1381 patients with IRD, 1035 received a genetic diagnosis. The prevalence of patients with *USH2A* mutations was 15.75% (n=163), making *USH2A* the most frequently mutated gene in this cohort of patients with IRD. The mean age was 42.85±15.37 years (range, 2–80 years; median, 43 years) in our cohort of 93 men and 70 women. **Table 1** shows the demographic and clinical characteristics. Eighty-eight patients (53.99%, 88/163) from 77 families were diagnosed with USH2 (40.19±15.32 years), and 75 patients (46.01%, 75/163) from 70 families were diagnosed with RP (45.85±14.96 years).

Phenotypic studies

The median age of onset of patients with USH2 was 15.34±12.62 years (range 0–46), which was younger than that of patients with RP (23.37±15.72 years; range 0–64; p<0.05). There was no difference in mean BCVA or CFT between RP and USH2 groups

overall, but when dividing the cohort into patients younger and older than 50 years, the difference became statistically significant (p<0.05). The VF and CFT were impaired more severely in patients with USH2 (-26.59±3.61 dB, 210.75±39.63 μm) than in patients with RP (-23.73±6.45 dB, 232.39±49.93 μm) younger than 50 years (p<0.01 and p<0.05, respectively), whereas BCVA was impaired more severely in patients with USH2 (0.11±0.22) older than 50 years (p<0.05, **table 1**). In the first decade from disease onset, BCVA, VF and CFT declined in both groups, but VF and CFT declined more severely in patients with USH2 (-26.26±3.28 dB, 224.00±33.03 μm) than in patients with RP (-20.71±7.45 dB, 256.67±52.76 μm; p<0.05); nevertheless, the differences became insignificant as the disease progressed (p>0.05). Moreover, BCVA in both groups and VF and CFT in the RP group declined with disease progression (p<0.05), whereas progression of VF and CFT in patients with USH2 did not differ significantly between patients with a disease course >10 years and that <10 years (p>0.05).




Figure 1 Proportions of *USH2A* gene mutations in patients with retinitis pigmentosa (RP) and Usher syndrome type II (USH2) in this study. (A) The proportion of different mutations types in patients with RP and USH2. (B) The proportion of different combinations of mutations types in patients with RP and USH2. M, missense; SFNO, splice site, nonsense, frameshift, or other (readthrough, gross deletions and small indels).

Legal blindness due to VF loss occurred within 10 years after disease onset in patients with USH2, whereas VF loss in patients with RP was relatively comparable to that in patients with USH2 only 10 years after disease onset ($p > 0.05$). All of these results indicate that patients with USH2 have an earlier and more serious decline of visual function and damage to retinal structure than patients with RP in the first 10 years after onset, but that visual prognosis between the two groups does not differ when the course of disease exceeds 10 years.

To better assess disease progression and the difference between the two groups, we assessed correlations among disease duration, age, BCVA, MD and CFT using correlation analysis (table 2). Results showed that BCVA decreased significantly with disease progression and age in both patients with RP and USH2 ($p < 0.01$), but MD and CFT were not correlated with disease progression or age ($p > 0.05$). Thus, the rate of disease progression may depend on the initial diagnosis or the course of the disease and on other key factors.

Genetic studies

A total of 344 mutations were identified, of which 197 (57.27%) were missense, 33 were nonsense, 43 were frameshift, 64 were splice-site, 3 were readthrough, 3 were gross deletions and 1 a small indel. The most common mutations were c.2802T >G (11.88%) and c.8559-2A >G (9.28%), accounting for 21.16% of all mutations. It is likely that these two variants represent a hotspot of *USH2A* in the Chinese population. Six mutations, c.99_100insT, c.11156G >A, c.15178T >C, c.4821G >C, c.8232G >C and c.9469C >T, accounted for another 15.94% of the total. Of the 156 distinct variants identified in this study, 84 were novel, including 13 pathogenic variants, 32 likely pathogenic variants and 39 variants of uncertain significance (see online supplementary table 1). Of the 163 patients

with pathogenic mutations on both alleles, 14 (8.59%) were homozygous and 149 (91.41%) were compound heterozygous. Only eight distinct pathogenic homozygous mutations were detected, of which four (c.15575_15579delAGGAA, c.8232G >C, c.8559-2A >G, c.99_100insT) were associated with USH2 and four (c.11156G >A, c.13465G >A, c.2802T >G, c.4616C >T) with RP. These variants are presumed to be USH2 or RP specific. Additionally, one de novo mutation (c.2802T >G) was identified in the 54 trios (1.85%).

Genotype–phenotype correlations

Of all the *USH2A* mutations associated with RP ($n=158$), 77.22% ($n=122$) were missense variants and 22.78% ($n=21$) were nonsense ($n=11$), frameshift ($n=7$), or splice-site mutations ($n=18$) that severely affected protein function. In the USH2 group ($n=187$), which had a severe early-onset clinical presentation, only 40.64% ($n=76$) mutations were missense and 59.36% were non-missense, including splice-site ($n=46$), frameshift ($n=36$), nonsense ($n=22$), readthrough ($n=3$), gross deletions ($n=3$) and small indels ($n=1$) (figure 1). Moreover, of all the patients with RP, 39 (52%) had missense +missense (M+M) mutations and 36 (48%) had missense +splice-site/frameshift/nonsense mutations (M+SFNO); no patients with SFNO+SFNO mutations were identified. However, in patients with USH2, only 7 (8%) patients had M+M mutations, 52 (59%) had M+SFNO and 29 (33%) had SFNO+SFNO mutations. These results suggested that USH2 was associated with a more severe genotype.

To further understand the relationship between genotype and clinical features, we stratified all patients into three groups: group I comprised patients with M+M mutations, group II had patients with M+SFNO mutations and group III had patients with SFNO +SFNO mutations. Then, BCVA, MD and CFT of the three groups were compared and analysed (tables 3 and 4). Overall, 84.78% (39/46) of the patients in group I and 40.91% (36/88) in group II had RP, whereas all patients in group III had USH2 (no patients with RP were identified in group III). Moreover, the median age of onset of group III (12.59 ± 11.37 years) was earlier than that of patients in group I (22.74 ± 14.86 years) or group II (19.32 ± 14.92 years; $p < 0.001$). These results suggested that SFNO mutations in *USH2A* were associated mostly with USH2 ($p < 0.001$) and resulted in an earlier onset of disease. We found no significant differences in mean duration, BCVA, MD or CFT among the three groups, although BCVA decreased significantly with disease progression in all groups ($p < 0.001$). We found no significant correlations between disease duration and MD or CFT in the three groups ($p > 0.05$), indicating that MD and CFT progression were not directly related to mutation type.

DISCUSSION

In this study, we provide a brief overview of *USH2A* mutation frequency in a large cohort of Chinese patients. Of the 1035 patients with IRD, 163 had mutations in *USH2A*; this prevalence (15.75%) being the highest of patients with IRD in this study population. Additionally, 53.99% were diagnosed with USH2 and 46.01% were diagnosed with RP, indicating a relatively balanced clinical profile of *USH2A*-associated diseases in this population. These data provide valuable information for researchers in gene therapy as well as economists and government policy-makers.

Pierrache *et al* have described genotype–phenotype correlations and compared visual prognosis in USH2 and RP in a large

Table 3 Clinical characteristics of patients with different types of *USH2A* mutations

	M+M (n=46)	M+SNFO (n=88)	SNFO+SNFO (n=20)	Significant (P value)
Patients (RP/USH2)	39/7	36/52	0/29	1:<0.001 2:<0.001 3:<0.001
Onset age, yrs	22.74±14.86	19.32±14.92	12.59±11.37	1:0.108 2:<0.001 3:<0.001
Duration, yrs	23.18±16.13	25.28±15.98	21.54±14.00	1:0.360 2:0.539 3:0.119
BCVA*	0.35±0.31	0.34±0.30	0.40±0.33	1:0.932 2:0.407 3:0.336
Duration, ≤10 years	0.57±0.27	0.50±0.32	0.66±0.18	1:0.408 2:0.329 3:0.080
Duration, 10–20 years	0.46±0.29	0.41±0.33	0.54±0.37	1:0.617 2:0.569 3:0.273
Duration, >20 years	0.22±0.26	0.26±0.25	0.20±0.19	1:0.403 2:0.670 3:0.209
MD*, dB	-24.83±5.62	-25.43±4.32	-25.62±4.66	1:0.511 2:0.245 3:0.444
Duration, ≤10 years	-22.32±7.05	-22.58±6.04	-23.96±2.99	1:0.387 2:0.196 3:0.343
Duration, 10–20 years	-24.11±3.03	-25.75±4.03	-25.00±4.51	1:0.596 2:0.998 3:0.367
Duration, >20 years	-25.60±4.68	-26.96±2.57	-26.63±4.72	1:0.331 2:0.365 3:0.480
CFT*, μm	250.43±68.66	229.34±67.86	230.38±76.44	1:0.098 2:0.126 3:0.585
Duration, ≤10 years	282.10±105.39	281.72±86.18	250.70±99.36	1:0.826 2:0.157 3:0.276
Duration, 10–20 years	256.24±52.26	238.22±33.58	232.25±22.25	1:0.170 2:0.456 3:0.961
Duration, >20 years	218.00±31.57	199.50±45.98	197.75±65.60	1:0.488 2:0.873 3:0.137

1: M+M versus M+SNFO; 2: M+M versus SNFO+SNFO; 3: M+SNFO versus SNFO+SNFO.

*Corrected for the time of disease duration.

M, missense; SNFO, splice-site, nonsense, frameshift, or others (readthrough, gross deletions and small indels).

RP, retinitis pigmentosa; USH2, Usher syndrome type IIa; BCVA, best Snellen corrected visual acuity; MD, mean deviation; CFT, centre foveal thickness.

cohort of patients with *USH2A* mutations,⁴ but all their participants were of European origin. It is uncertain whether the same conclusions would be reached in a Chinese population and, to date, the underlying genetic and phenotypic characteristics of Chinese patients with *USH2A* mutations have not been comprehensively explored. In this study, we found that patients with USH2 had an earlier and more severe decline of visual function and damage to the retinal structure than did patients with RP in the first decade from disease onset, which is consistent with a previous study.⁴ However, our study confirmed that the progression of RP accelerated in the second decade of the disease, and that there was no difference in visual prognosis between patients with USH2 and RP when the disease duration exceeded 10 years. These data indicate that the optimal intervention window for subretinal gene therapy is within the first decade from disease onset.

Table 4 Correlations of best Snellen corrected visual acuity (BCVA), mean deviation (MD) and central foveal thickness (CFT) with disease duration in patients with different types of *USH2A* mutations

	M+M		M+SNFO		SNFO+SNFO	
	r	P value	r	P value	r	P value
BCVA versus duration	-0.574	<0.001	-0.284	0.001	-0.528	<0.001
≤10 years	-0.433	0.025	-0.444	0.012	-0.684	0.031
-10 to 20 years	-0.152	0.338	-0.339	0.045	-0.132	0.327
>20 years	-0.384	0.005	-0.002	0.493	-0.038	0.436
MD versus duration	-0.315	0.027	-0.245	0.024	-0.239	0.155
≤10 years	-0.300	0.171	-0.030	0.454	-0.120	0.411
-10 to 20 years	-0.894	0.053	-0.352	0.108	-0.894	0.053
>20 years	-0.525	0.006	-0.220	0.106	-0.303	0.197
CFT versus duration	-0.177	0.154	-0.455	<0.001	-0.01	0.481
≤10 years	-0.773	-0.004	-0.04	0.437	-0.894	0.053
-10 to 20 years	-0.051	0.452	-0.013	0.480	-0.049	0.446
>20 years	-0.673	0.002	-0.540	0.007	-0.278	0.219

BCVA, best Snellen corrected visual acuity; CFT, center foveal thickness; M, missense; MD, mean deviation; RP, retinitis pigmentosa; SNFO, splice-site, nonsense, frameshift, or others (readthrough, gross deletions and small indels); USH2, Usher syndrome type IIa.

Consistent with previous studies, the hotspot of *USH2A* was c.8559-2A >G in Chinese and Japanese patients,^{12 13} but hotspot of *USH2A* in European patients (p.Glu767Serfs*21 and p.Cys759Phe) was not detected in this study.^{7 10} Besides, we found that c.2802T>G was a *USH2A* mutation hotspot in our cohort of Chinese patients. We also identified 84 novel variants, confirming that the mutation spectrum of *USH2A* in Chinese patients differs from that of other populations. Thus far, it is unknown why some mutations in *USH2A* lead to USH2 and others to RP. As most patients are compound heterozygotes, it is difficult to assess the effect of individual mutations on the phenotype. Nevertheless, variants in the homozygous state represent an ideal model by which to search for disease-specific alleles. Previous studies found that five variants (c.2802T >G, c.10073G>A, c.11156G>A, c.12295-3T>A and c.12575G>A) are RP specific, and three (c.12295-3T>A, c.9056-2A>G, and c.5776+1G>A) are USH2 specific.³ Further data from our cohort showed that c.13465G>A, c.4616C>T, and two reported variants, c.2802T>G and c.11156G>A, were specific to RP, whereas c.15575_15579delAGGAA, c.8232G>C, c.8559-2A>G and c.99_100insT were specific to USH2. A known genotype would allow for better correlation of clinical signs and counselling of patients.

In patients with RP, 77.22% of *USH2A* mutations were missense, whereas in patients with USH2, only 40.64% of mutations were missense; all other mutations were nonsense, frameshift or splice-site mutations that severely affected protein function. This may imply that missense variants in *USH2A* have less severe consequences and are therefore found more commonly in the milder RP than in the more severe USH2. Each RP genotype documented included at least one missense variant, whereas the two deleterious mutations were restricted to the USH2 phenotype, consistent with previous reports.⁴ We hypothesise that RP results from genotypes that include milder hypomorphic alleles; further experimental verification of this hypothesis is needed. We further explored this observation by analysing the relationship between genotype and clinical features of *USH2A* mutations, which confirmed that more deleterious genotypes, including frameshift, nonsense, gross deletions and small indels, were associated with an earlier onset of disease, regardless of the phenotype. The disease progression rate was

not directly related to the genotype; thus, additional genetic or environmental modifiers may play a role in disease progression.

In summary, we presented the overall frequency of *USH2A*-associated IRD and a detailed clinical and genetic characterisation of patients of Chinese origin with *USH2A* mutations. We found that missense variants had less severe consequences and were found more commonly in the milder RP; the more deleterious genotypes were associated with an earlier onset of disease. Although the rate of disease progression was not directly related to genotype, we found no difference in visual prognosis among patients with *USH2A* mutations when the course of disease exceeded 10 years. Our data provide a deeper understanding of *USH2A* mutations in China and enable precise genetic diagnoses and better management of these patients, and serve as a well-founded reference for genetic counselling and development of potential therapeutic approaches.

Author affiliations

¹Eye Institute, Eye and ENT Hospital, College of Medicine, Fudan University, Shang Hai, China

²Shanghai Key Laboratory of Visual Impairment and Restoration, Science and Technology Commission of Shanghai Municipality, Shang Hai, China

³Key Laboratory of Myopia (Fudan University), Chinese Academy of Medical Sciences, National Health Commission, Shang Hai, China

⁴Laboratory of Genomics and Molecular Biomedicine, Department of Biology, University of Copenhagen, Copenhagen, Denmark

⁵Shenzhen Engineering Laboratory for Birth Defects Screening, BGI-Shenzhen, Shenzhen, China

⁶BGI-Shenzhen, Shenzhen, China

⁷Sonoma Academy, Santa Rosa, CA

⁸Dept of Computer Science, City University of Hong Kong, Hong Kong, China

⁹BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, China

Twitter Feng-Juan Gao @gfj

Acknowledgements The author would like to thank all the participants and staff for their valuable contribution to this research.

Contributors J-HW conceived and designed the experiments. WL, QC, PX, J-HW, F-JG, D-DW and Y-HQ collected the clinical samples. F-JG, J-HW, H-XS, F-YH, JL, FC, WL and D-DW analysed sequencing data. G-ZX, WL, F-JG and Y-HQ recruited patients, performed clinical examination of patients and clinical interpretation. F-JG and J-HW drafted and revised the manuscript.

Funding Supported by the National Natural Science Foundation of China (Grant NSFC81770925, 81790641), Xuhui District Health and Family Planning Commission Key Disease Joint Project (XHLHGG201807), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT32019, Shanghai Municipal Science and Technology Major Projects (2018SHZDZX05), Shanghai Clinical Medical Center of Ocular Disease (2017ZZ01020).

Competing interests None declared.

Patient consent for publication Parental or guardian consent obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Feng-Juan Gao <http://orcid.org/0000-0002-2799-3554>

Wei Liu <http://orcid.org/0000-0002-6861-5752>

Qing Chang <http://orcid.org/0000-0003-4288-9736>

REFERENCES

- Ng TK, Tang W, Cao Y, *et al*. Whole exome sequencing identifies novel *USH2A* mutations and confirms Usher syndrome 2 diagnosis in Chinese retinitis pigmentosa patients. *Sci Rep* 2019;9:5628.
- Adato A, Lefèvre G, Delprat B, *et al*. Usherin, the defective protein in Usher syndrome type IIA, is likely to be a component of interstereocilia ankle links in the inner ear sensory cells. *Hum Mol Genet* 2005;14:3921–32.
- Lenassi E, Vincent A, Li Z, *et al*. A detailed clinical and molecular survey of subjects with nonsyndromic *USH2A* retinopathy reveals an allelic hierarchy of disease-causing variants. *Eur J Hum Genet* 2015;23:1318–27.
- Pierrache LHM, Hartel BP, van Wijk E, *et al*. Visual prognosis in *USH2A*-Associated retinitis pigmentosa is worse for patients with Usher syndrome type IIA than for those with nonsyndromic retinitis pigmentosa. *Ophthalmology* 2016;123:1151–60.
- Sun T, Xu K, Ren Y, *et al*. Comprehensive molecular screening in Chinese Usher syndrome patients. *Invest Ophthalmol Vis Sci* 2018;59:1229–37.
- Gao F-J, Li J-K, Chen H, *et al*. Genetic and clinical findings in a large cohort of Chinese patients with suspected retinitis pigmentosa. *Ophthalmology* 2019;126:1549–56.
- Blanco-Kelly F, Jaijo T, Aller E, *et al*. Clinical aspects of Usher syndrome and the *USH2A* gene in a cohort of 433 patients. *JAMA Ophthalmol* 2015;133:157–64.
- Aller E, Larrieu L, Jaijo T, *et al*. The *USH2A* c.2299delG mutation: dating its common origin in a southern European population. *Eur J Hum Genet* 2010;18:788–93.
- Bernal S, Ayuso C, Antiñolo G, *et al*. Mutations in *USH2A* in Spanish patients with autosomal recessive retinitis pigmentosa: high prevalence and phenotypic variation. *J Med Genet* 2003;40:e8.
- Le Quesne Stabej P, Saihan Z, Rangesh N, *et al*. Comprehensive sequence analysis of nine Usher syndrome genes in the UK national collaborative Usher study. *J Med Genet* 2012;49:27–36.
- Huang X-Y, Zhuang H, Wu J-H, *et al*. Targeted next-generation sequencing analysis identifies novel mutations in families with severe familial exudative vitreoretinopathy. *Mol Vis* 2017;23:605–13.
- Nakanishi H, Ohtsubo M, Iwasaki S, *et al*. Identification of 11 novel mutations in *USH2A* among Japanese patients with Usher syndrome type 2. *Clin Genet* 2009;76:383–91.
- Jiang L, Liang X, Li Y, *et al*. Comprehensive molecular diagnosis of 67 Chinese Usher syndrome probands: high rate of ethnicity specific mutations in Chinese USH patients. *Orphanet J Rare Dis* 2015;10:110.

Ptients ID	Sex	Age	Diagnosis	dBHL	Gene	Nucleotide change	Amino acid change	Zygosis	Reported	Category
RD16100083	F	61	RP	19	<i>USH2A</i>	c.6325+1G>A	-	Het	Yes	P
					<i>USH2A</i>	c.5200G>C	p.Gly1734Arg	Het	Yes	P
RD16121768	M	37	USH2	56	<i>USH2A</i>	c.11241_11242insT TAC	p.Tyr3747TyrfsX15	Het	No	LP
					<i>USH2A</i>	c.2802T>G	p.Cys934Trp	Het	Yes	P
RD16122951	F	38	USH2	52	<i>USH2A</i>	c.15575_15579delAG GAA	p.Lys5192ThrfsX?	Het	No	LP
					<i>USH2A</i>	c.9469C>T	p.Gln3157*	Het	Yes	P
RD16122952	M	9	USH2	47	<i>USH2A</i>	c.15575_15579delAG GAA	p.Lys5192ThrfsX?	Hom	No	LP
R0161206600	F	52	USH2	51	<i>USH2A</i>	c.7018_7019 delCA	p.Gln2340GlyfsX16	Het	No	LP
					<i>USH2A</i>	c.4821G>C	p.Trp1607Cys	Het	No	LP
R0161206601	M	61	USH2	55	<i>USH2A</i>	c.7018_7019 delCA	p.Gln2340GlyfsX16	Het	No	LP
					<i>USH2A</i>	c.4821G>C	p.Trp1607Cys	Het	No	LP
R0161007602	M	52	USH2	52	<i>USH2A</i>	c.7018_7019 delCA	p.Gln2340GlyfsX16	Het	No	LP
					<i>USH2A</i>	c.4821G>C	p.Trp1607Cys	Het	No	LP
R0161206803	F	58	USH2	52	<i>USH2A</i>	c.7018_7019 delCA	p.Gln2340GlyfsX16	Het	No	LP
					<i>USH2A</i>	c.4821G>C	p.Trp1607Cys	Het	No	LP
R0161206604	F	47	USH2	49	<i>USH2A</i>	c.7018_7019 delCA	p.Gln2340GlyfsX16	Het	No	LP
					<i>USH2A</i>	c.4821G>C	p.Trp1607Cys	Het	No	LP
R0161006605	F	43	USH2	57	<i>USH2A</i>	c.7018_7019 delCA	p.Gln2340GlyfsX16	Het	No	LP
					<i>USH2A</i>	c.4821G>C	p.Trp1607Cys	Het	No	LP
RD17011488	M	34	USH2	47	<i>USH2A</i>	c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i>	c.6239_6240insA	p.Lys2080LysfsX23	Het	No	LP
RD17020641	F	59	RP	20	<i>USH2A</i>	c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i>	c.2802T>G	p.Cys934Trp	Het	Yes	P
RD17021722	F	56	RP	19	<i>USH2A</i>	c.10733G>A	p.Ser3578Asn	Het	No	VUS
					<i>USH2A</i>	c.8559-2A>G	-	Het	Yes	P
R0170400746	M	38	RP	18	<i>USH2A</i>	c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i>	c.14404T>C	p.Ser4802Pro	Het	No	VUS
RD17043134	F	51	RP	20	<i>USH2A</i>	c.14285A>T	p.Asn4762Ile	Het	No	VUS
					<i>USH2A</i>	c.14017T>C	p.Tyr4673His	Het	Yes	P
					<i>USH2A</i>	c.2802T>G	p.Cys934Trp	Het	Yes	P
RD17043137	M	67	RP	19	<i>USH2A</i>	c.15095G>A	p.Ser5032Asn	Het	No	VUS
					<i>USH2A</i>	c.14642G>C	p.Ser4881Thr	Het	No	VUS
RD17050476	M	65	USH2	40	<i>USH2A</i>	c.7399_7400insAATAA CGCTCCTGGCTCTC	p.Pro2467GlnfsX2	Het	No	LP
					<i>USH2A</i>	c.1644+4A>G	-	Het	No	VUS
RD17050478	F	80	USH2	52	<i>USH2A</i>	c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i>	c.1644+4A>G	-	Het	No	VUS
RD17050721	F	41	RP	17	<i>USH2A</i>	c.8575C>T	p.Arg2859Cys	Het	No	VUS
					<i>USH2A</i>	c.8440G>A	p.Val2814Ile	Het	No	VUS
RD17050879	M	29	USH2	38	<i>USH2A</i>	c.8232G>C	p.Trp2744Cys	Hom	Yes	P
RD1706090	F	29	USH2	50	<i>USH2A</i>	c.8232G>C	p.Trp2744Cys	Hom	Yes	P
RD1706066	F	43	USH2	41	<i>USH2A</i>	c.9469C>T	p.Gln3157*	Het	Yes	P
					<i>USH2A</i>	c.7037A>G	p.His2346Arg	Het	No	VUS
RD18060479	M	40	USH2	46	<i>USH2A</i>	c.9469C>T	p.Gln3157*	Het	Yes	P
					<i>USH2A</i>	c.7037A>G	p.His2346Arg	Het	No	VUS
RD18010625	M	48	USH2	42	<i>USH2A</i>	c.12790G>A	p.Glu4264Lys	Het	Yes	VUS
					<i>USH2A</i>	c.8559-2A>G	-	Het	Yes	P
R017100493	F	50	RP	19	<i>USH2A</i>	c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i>	c.13811+1delG	-	Het	No	LP
R017060523	M	26	USH2	50	<i>USH2A</i>	c.8284C>G	p.Pro2762Ala	Het	Yes	P

					<i>USH2A</i> c.9958G>T	p.Gly3320Cys	Het	Yes	P
					<i>USH2A</i> c.13040_13062delinsTC	p.Thr4347ifs	Het	No	P
					AGAAGTCA				
R017100416	F	37	RP	19	<i>USH2A</i> c.13465G>A	p.Gly4489Ser	Het	Yes	P
					<i>USH2A</i> c.10190_10191delAA	p.Lys3397ArgfsX20	Het	Yes	P
R018090252	M	23	USH2	50	<i>USH2A</i> c.5836C>T	p.Arg1946*	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
R017090333	F	46	USH2	45	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> c.3314A>C	p.Tyr1105Ser	Het	No	VUS
RD18050819	M	10	RP	20	<i>USH2A</i> c.12790G>A	p.Glu4264Lys	Het	Yes	VUS
					<i>USH2A</i> c.11549-5delT	-	Het	No	LP
					<i>USH2A</i> c.6998T>C	p.Val2333Ala	Het	Yes	VUS
RD18050569	F	36	USH2	44	<i>USH2A</i> c.10576C>T	p.Gln3526*	Het	No	P
					<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
RD17090325	F	28	USH2	48	<i>USH2A</i> c.14223_14224insC	-	Het	No	LP
					<i>USH2A</i> c.7300+1G>T	-	Het	No	LP
R017090110	F	51	RP	20	<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD18050019	M	22	USH2	56	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> EX17_21 DEL	-	Het	Yes	P
RD18080622	M	26	RP	19	<i>USH2A</i> c.11683G>A	p.Gly3895Arg	Het	No	LP
					<i>USH2A</i> c.9593A>G	p.Tyr3198Cys	Het	No	VUS
R017070069	F	44	USH2	53	<i>USH2A</i> c.538T>C	p.Ser180Pro	Het	Yes	P
					<i>USH2A</i> c.99_100insT	p.Ser33SerfsX42	Het	Yes	P
RD17120980	M	40	RP	20	<i>USH2A</i> c.9915G>C	p.Glu3305Asp	Het	Yes	VUS
					<i>USH2A</i> c.7068T>G	p.Asn2356Lys	Het	Yes	P
R01706066	M	57	RP	18	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i> c.2855C>G	p.Ser952*	Het	No	P
RD17061067	M	33	RP	19	<i>USH2A</i> c.11156G>A	p.Arg3719His	Hom	Yes	P
RD17061138	M	49	USH2	49	<i>USH2A</i> c.9469C>T	p.Gln3157*	Het	Yes	P
					<i>USH2A</i> c.6325+1G>A	-	Het	Yes	P
RD17072130	M	48	RP	20	<i>USH2A</i> c.10859T>C	p.Ile3620Thr	Het	Yes	P
					<i>USH2A</i> c.6071C>T	p.Pro2024Leu	Het	No	VUS
RD17080296	M	30	USH2	56	<i>USH2A</i> c.13202G>A	p.Gly4401Asp	Het	No	VUS
					<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> c.3788G>A	p.Trp1263*	Het	Yes	P
RD17080301	M	16	RP	19	<i>USH2A</i> c.12790G>A	p.Glu4264Lys	Het	Yes	VUS
					<i>USH2A</i> c.11198_11199insA	p.Asn3733Lysfs4	Het	No	LP
RD17082179	F	38	RP	20	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i> c.2168-1G>C	-	Het	Yes	P
RD17091313	M	15	USH2	55	<i>USH2A</i> c.3883C>T	p.Arg1295*	Het	Yes	P
					<i>USH2A</i> c.99_100insT	p.Ser33Serfs42	Het	Yes	P
RD17094479	M	38	RP	19	<i>USH2A</i> c.13465G>A	p.Gly4489Ser	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
DP17100401	F	32	RP	20	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD17101069	F	58	USH2	49	<i>USH2A</i> c.6310_6325delAACT	p.Asn2104Ilefs2	Het	No	LP
					ACATAGTCACAG				
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD17101995	F	48	RP	19	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD17110028	M	26	USH2	41	<i>USH2A</i> c.11548+1G>A	-	Het	No	P
					<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
RD17110186	M	45	RP	20	<i>USH2A</i> c.13339A>G	p.Met4447Val	Het	Yes	VUS

					<i>USH2A</i> c.2653C>T	p.His885Tyr	Het	Yes	P
RD17111447	F	45	RP	20	<i>USH2A</i> c.13502C>A	p.Pro4501Gln	Het	No	VUS
					<i>USH2A</i> c.11864G>A	p.Trp3955*	Het	Yes	P
RD17111461	M	36	USH2	39	<i>USH2A</i> c.12560G>A	p.Arg4187His	Het	Yes	VUS
					<i>USH2A</i> c.1724G>A	p.Cys575Tyr	Het	Yes	P
RD17113982	F	42	RP	18	<i>USH2A</i> c.13480T>C	p.Tyr4494His	Het	No	VUS
					<i>USH2A</i> c.13339A>G	p.Met4447Val	Het	Yes	VUS
RD17123978	M	36	USH2	34	<i>USH2A</i> c.9469C>T	p.Gln3157*	Het	Yes	P
					<i>USH2A</i> c.4818_4819insA	p.Lys1606Lysfs4	Het	No	LP
RD17124982	M	2	RP	17	<i>USH2A</i> c.13004C>A	p.Ala4335Asp	Het	No	VUS
					<i>USH2A</i> c.8095C>T	p.Arg2699Trp	Het	No	VUS
RD17124002	M	48	USH2	56	<i>USH2A</i> c.14065delA	p.Ile4689Serfs10	Het	No	LP
					<i>USH2A</i> c.6661T>C	p.Cys2221Arg	Het	No	VUS
RD17124989	M	43	USH2	48	<i>USH2A</i> c.14065delA	p.Ile4689Serfs10	Het	No	LP
					<i>USH2A</i> c.6661T>C	p.Cys2221Arg	Het	No	VUS
RD17124003	F	53	RP	19	<i>USH2A</i> c.6929C>T	p.Thr2310Met	Het	No	VUS
					<i>USH2A</i> c.1757A>C	p.Tyr586Ser	Het	No	VUS
RD17125000	F	46	USH2	53	<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.538T>C	p.Ser180Pro	Het	Yes	P
RD17126053	F	50	RP	20	<i>USH2A</i> c.10331G>A	p.Cys3444Tyr	Het	Yes	P
					<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
RD18010305	F	44	RP	20	<i>USH2A</i> c.12752G>T	p.Ser4251Ile	Het	No	VUS
					<i>USH2A</i> c.8638_8633dup	p.Ser2881Leufs*9	Het	No	LP
RD18010588	F	43	RP	19	<i>USH2A</i> c.5204G>A	p.Gly1735Glu	Het	No	VUS
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD18012919	F	31	RP	17	<i>USH2A</i> c.9958G>T	p.Gly3320Cys	Het	Yes	P
					<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.8284C>G	p.Pro2762Ala	Het	Yes	P
RD18012995	M	34	USH2	52	<i>USH2A</i> c.11806A>C	p.Thr3936Pro	Het	Yes	P
					<i>USH2A</i> c.2167+1G>A	–	Het	No	P
RD18021256	M	70	USH2	50	<i>USH2A</i> c.13202G>A	p.Gly4401Asp	Het	No	VUS
					<i>USH2A</i> c.3788G>A	p.Trp1263*	Het	Yes	P
RD18021276	M	38	RP	20	<i>USH2A</i> c.9699delT	p.His3234Ilefs*67	Het	No	LP
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD18034505	M	31	USH2	47	<i>USH2A</i> c.8232G>C	p.Trp2744Cys	Het	Yes	P
					<i>USH2A</i> c.8224-1G>C	–	Het	No	LP
RD18036958	M	32	USH2	51	<i>USH2A</i> c.11389+1G>C	–	Het	Yes	P
					<i>USH2A</i> c.8232G>C	p.Trp2744Cys	Het	Yes	P
RD18040300	M	78	RP	19	<i>USH2A</i> c.10859T>C	p.Ile3620Thr	Het	Yes	P
					<i>USH2A</i> c.10712C>T	p.Thr3571Met	Het	Yes	P
RD18040317	M	62	USH2	48	<i>USH2A</i> c.13121T>A	p.Val4374Glu	Het	No	VUS
					<i>USH2A</i> c.12361C>T	p.Arg4121Cys	Het	No	VUS
RD18040329	M	36	USH2	51	<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.802G>A	p.Gly268Arg	Het	Yes	P
RD18041215	F	41	USH2	46	<i>USH2A</i> c.11648T>C	p.Ile3883Thr	Het	No	VUS
					<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.769G>A	p.Gly257Arg	Het	Yes	VUS
RD18043350	M	50	USH2	51	<i>USH2A</i> c.4645C>T	p.Arg1549*	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i> c.2653C>T	p.His885Tyr	Het	Yes	P
RD18043388	F	72	USH2	60	<i>USH2A</i> c.6325+1G>A	–	Het	Yes	P
					<i>USH2A</i> c.3667T>C	p.Cys1223Arg	Het	No	VUS
					<i>USH2A</i> c.905G>A	p.Cys302Tyr	Het	No	LP
RD18071376	M	66	USH2	42	<i>USH2A</i> c.6325+1G>A	–	Het	Yes	P

					<i>USH2A</i> c.3667T>C	p.Cys1223Arg	Het	No	VUS
					<i>USH2A</i> c.905G>A	p.Cys302Tyr	Het	No	LP
RD1805172	M	58	USH2	55	<i>USH2A</i> c.99_100insT	p.Arg34Serfs41	Hom	Yes	P
RD18184100	F	61	USH2	50	<i>USH2A</i> c.14876G>T	p.Gly4959Val	Het	No	VUS
					<i>USH2A</i> c.3829G>T	p.Glu1277*	Het	No	P
RD18184118	F	28	USH2	52	<i>USH2A</i> c.11994C>A	p.Tyr3998*	Het	Yes	P
					<i>USH2A</i> c.5152C>T	p.Gln1718*	Het	No	P
RD18184129	M	51	USH2	59	<i>USH2A</i> c.14404T>C	p.Ser4802Pro	Het	No	VUS
					<i>USH2A</i> c.13510G>T	p.Glu4504*	Het	No	P
RD18070019	F	56	RP	18	<i>USH2A</i> c.13202G>A	p.Gly4401Asp	Het	No	VUS
					<i>USH2A</i> c.5162G>A	p.Gly1721Glu	Het	No	VUS
					<i>USH2A</i> c.3788G>A	p.Trp1263*	Het	Yes	P
RD18070019	F	53	RP	20	<i>USH2A</i> c.13202G>A	p.Gly4401Asp	Het	No	VUS
					<i>USH2A</i> c.5162G>A	p.Gly1721Glu	Het	No	VUS
					<i>USH2A</i> c.3788G>A	p.Trp1263*	Het	Yes	P
RD18071422	F	29	RP	21	<i>USH2A</i> c.13465G>A	p.Gly4489Ser	Het	Yes	P
					<i>USH2A</i> c.9022_9023insA	p.Ser3008Lysfs45	Het	No	LP
RD18073491	M	29	RP	18	<i>USH2A</i> c.12697T>C	p.Trp4233Arg	Het	Yes	vus
					<i>USH2A</i> c.4124C>T	p.Ser1375Leu	Het	No	vus
RD18073538	M	23	USH2	50	<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.6325+1G>A	–	Het	Yes	P
RD18113679	M	46	USH2	49	<i>USH2A</i> c.14792_14793insT	p.Leu4931Phefs23	Het	No	LP
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD18113666	F	43	RP	22	<i>USH2A</i> c.9958G>T	p.Gly3320Cys	Het	Yes	P
					<i>USH2A</i> c.8284C>G	p.Pro2762Ala	Het	Yes	P
					<i>USH2A</i> c.4021G>C	p.Ala1341Pro	Het	No	VUS
RD18102634	F	69	RP	20	<i>USH2A</i> c.14570G>T	p.Gly4857Val	Het	No	LP
					<i>USH2A</i> c.2167+5G>A	–	Het	Yes	P
					<i>USH2A</i> c.503C>T	p.Thr168Ile	Het	No	VUS
RD18093274	F	59	USH2	58	<i>USH2A</i> c.9958G>T	p.Gly3320Cys	Het	Yes	P
					<i>USH2A</i> c.9676C>T	p.Arg3226*	Het	Yes	LP
					<i>USH2A</i> c.8284C>G	p.Pro2762Ala	Het	Yes	P
RD18100638	M	52	USH2	52	<i>USH2A</i> c.9958G>T	p.Gly3320Cys	Het	Yes	P
					<i>USH2A</i> c.9676C>T	p.Arg3226*	Het	Yes	LP
					<i>USH2A</i> c.8284C>G	p.Pro2762Ala	Het	Yes	P
RD18100639	M	50	USH2	50	<i>USH2A</i> c.9958G>T	p.Gly3320Cys	Het	Yes	P
					<i>USH2A</i> c.9676C>T	p.Arg3226*	Het	Yes	LP
					<i>USH2A</i> c.8284C>G	p.Pro2762Ala	Het	Yes	P
RD1808689	M	57	USH2	50	<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.6325+1G>A	–	Het	Yes	P
RD1808628	F	36	USH2	55	<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
					<i>USH2A</i> c.99_100insT	p.Arg34Serfs41	Het	Yes	P
RD180882-1	M	33	USH2	48	<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
					<i>USH2A</i> c.99_100insT	p.Arg34Serfs41	Het	Yes	P
RD1808397	M	28	USH2	42	<i>USH2A</i> c.11389+1G>C	–	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD1808398	F	46	RP	20	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Hom	Yes	P
RD1808135	M	50	RP	21	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i> c.538T>C	p.Ser180Pro	Het	Yes	P
RD1808168	F	25	USH2	34	<i>USH2A</i> c.11389+1G>C	–	Het	Yes	P
					<i>USH2A</i> c.9244A>G	p.Ile3082Val	Het	Yes	P
					<i>USH2A</i> c.5264_5265insT	p.Val1756Argfs3	Het	No	LP
RD1808136	M	64	RP	24	<i>USH2A</i> c.13546G>T	p.Gly4516Trp	Het	Yes	LP
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P

RD1808174	M	68	RP	22	<i>USH2A</i> c.13546G>T	p.Gly4516Trp	Het	Yes	LP
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD1808401	F	58	RP	20	<i>USH2A</i> c.15520-1G>A	–	Het	No	LP
					<i>USH2A</i> c.10331G>A	p.Cys3444Tyr	Het	Yes	P
RD1904004	M	42	RP	20	<i>USH2A</i> c.11520_11523del	p.Tyr3840*fs1	Het	No	LP
					<i>USH2A</i> c.9801C>G	p.Cys3267Trp	Het	Yes	P
RD190332	F	46	USH2	56	<i>USH2A</i> c.15017C>T	p.Thr5006Met	Het	Yes	P
					<i>USH2A</i> c.1143+2T>C	–	Het	No	LP
RD19033249	F	47	RP	21	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
RD19033252	M	22	USH2	55	<i>USH2A</i> c.10342G>A	p.Glu3448Lys	Het	Yes	P
					<i>USH2A</i> c.5581G>A	p.Gly1861Ser	Het	Yes	P
RD18102594	M	51	USH2	50	<i>USH2A</i> c.8559-2A>G	–	Hom	Yes	P
RD18102620	M	32	RP	21	<i>USH2A</i> c.15427C>T	p.Arg5143Cys	Het	Yes	LP
					<i>USH2A</i> c.7068T>G	p.Asn2356Lys	Het	Yes	P
RD18110234	M	59	RP	21	<i>USH2A</i> c.10962C>	p.Tyr3654*	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD18110238	M	26	RP	19	<i>USH2A</i> c.14287G>C	p.Gly4763Arg	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD18125239	M	49	RP	20	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
RD18125290	M	34	RP	20	<i>USH2A</i> c.4616C>T	p.Thr1539Ile	Hom	Yes	P
RD18125302	M	30	RP	20	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i> c.10331G>A	p.Cys3444Tyr	Het	Yes	P
RD19022752	F	20	RP	19	<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
					<i>USH2A</i> c.9469C>T	p.Gln3157*	Het	Yes	P
RD19022753	M	52	RP	18	<i>USH2A</i> c.9469C>	p.Gln3157*	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD19022795	M	45	RP	20	<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
					<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
RD19022764	F	50	USH2	53	<i>USH2A</i> c.13877_13880del	p.Gln4626Profs7	Het	No	LP
					<i>USH2A</i> c.9237_9240del	p.Phe3080Leufs16	Het	No	LP
RD19022786	F	54	USH2	48	<i>USH2A</i> c.7594+1G>A	–	Het	Yes	P
					<i>USH2A</i> c.538T>C	p.Ser180Pro	Het	Yes	P
RD19020041	M	50	RP	20	<i>USH2A</i> c.7188G>A	p.Trp2396*	Het	No	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD1902199	M	45	USH2	44	<i>USH2A</i> c.11389+1G>C	–	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD19022706	F	47	RP	17	<i>USH2A</i> c.9047G>A	p.Cys3016Tyr	Het	No	VUS
					<i>USH2A</i> c.6492A>C	p.Lys2164Asn	Het	No	VUS
DP1908363	M	9	USH2	34	<i>USH2A</i> EX34_35DEL	–	Het	Yes	P
					<i>USH2A</i> c.7452-15_7452-5 delTTATTTC CAT	–	Het	No	VUS
DP19081631	F	30	USH2	41	<i>USH2A</i> c.8641_8642insTATT	p.Ser2881Leufs9	Het	No	LP
					<i>USH2A</i> c.2310_2311insA	p.Glu771Argfs8	Het	No	LP
RD19040022	M	55	RP	19	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i> c.14570G>T	p.Gly4857Val	Het	No	LP
DDP190031	M	64	RP	21	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i> c.14570G>T	p.Gly4857Val	Het	No	LP
RD190400A	F	33	USH2	38	<i>USH2A</i> c.15017C>T	p.Thr5006Met	Het	Yes	P
					<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
RD190332A	F	52	RP	22	<i>USH2A</i> c.6485+5G>A	–	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
RD180728A	M	46	USH2	39	<i>USH2A</i> c.8559-2A>G	–	Hom	Yes	P
RD180727A	M	78	RP	19	<i>USH2A</i> c.13465G>A	p.Gly4489Ser	Hom	Yes	P

RD181841B	M	25	RP	20	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i> c.14586T>G	p.Tyr4862*	Het	Yes	P
RD180430A	M	35	USH2	45	<i>USH2A</i> c.5298+2T>C	–	Het	No	LP
					<i>USH2A</i> c.7525C>T	p.Arg2509Trp	Het	Yes	P
DP18080533	F	66	USH2	52	<i>USH2A</i> c.11156G>A	p.Arg3719His	Het	Yes	P
					<i>USH2A</i> c.7068T>G	p.Asn2356Lys	Het	Yes	P
					<i>USH2A</i> c.4758+3A>G	–	Het	Yes	P
DP18086534	F	46	RP	19	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i> c.5329C>T	p.Arg1777Trp	Het	Yes	P
DP190056-1	F	58	RP	20	<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
DP1908968-1	F	67	RP	20	<i>USH2A</i> c.13274C>T	p.Thr4425Met	Het	Yes	P
					<i>USH2A</i> c.4251+1G>A	–	Het	Yes	P
DP18080005	M	25	USH2	51	<i>USH2A</i> c.9469C>T	p.Gln3157*	Het	Yes	P
					<i>USH2A</i> c.2914T>G	p.Cys972Gly	Het	Yes	P
DP18080539	M	35	RP	22	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i> c.3544T>C	p.Tyr1182His	Het	No	VUS
DP18085405	F	51	USH2	42	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> c.6741delC	p.Ala2249ProfsTer30	Het	Yes	P
DP19052236	M	57	RP	20	<i>USH2A</i> c.4576G>A	p.Gly1526Arg	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
DP18106566	M	65	RP	19	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
DP18065739	M	66	RP	21	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Hom	Yes	P
DP18085740	F	68	RP	19	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Hom	Yes	P
DTP1908103	M	35	USH2	50	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
					<i>USH2A</i> EX47Del	–	Het	Yes	P
DTP190109	M	30	USH2	50	<i>USH2A</i> c.252T>A	p.Cys84*	Het	No	P
					<i>USH2A</i> c.6485+1G>C	-	Het	No	LP
DTP1901698	M	49	USH2	39	<i>USH2A</i> c.8559-2A>G	–	Het	Yes	P
					<i>USH2A</i> c.10859T>C	p.Ile3620Thr	Het	Yes	P
DTP1810226	F	7	USH2	43	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> c.99_100insT	p.Ser33Serfs42	Het	Yes	P
DP180600600M	56	RP	19	<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P	
					<i>USH2A</i> c.11235C>G	p.Tyr3745*	Het	Yes	P
DP18036854	M	6	USH2	50	<i>USH2A</i> c.99_100insT	p.Ser33Serfs42	Hom	Yes	P
DP18126966	F	35	USH2	48	<i>USH2A</i> c.8232G>C	p.Trp2744Cys	Het	Yes	P
					<i>USH2A</i> c.7698T>A	p.Tyr2566*	Het	No	P
DTP1908998	F	40	RP	17	<i>USH2A</i> c.15178T>C	p.Ser5060Pro	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
DTP1910011	M	51	USH2	50	<i>USH2A</i> c.12358C>T	p.Arg4120Cys	Het	No	VUS
					<i>USH2A</i> c.8232G>C	p.Trp2744Cys	Het	Yes	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
DTP1900305	F	45	USH2	37	<i>USH2A</i> c.6485+5G>A	-	Het	Yes	P
					<i>USH2A</i> c.9422T>C	p.Leu3141Pro	Het	No	VUS
DTP1901225	M	37	RP	20	<i>USH2A</i> c.5485C>T	p.Cys1829*	Het	No	P
					<i>USH2A</i> c.2802T>G	p.Cys934Trp	Het	Yes	P
DTP190033	M	34	USH2	50	<i>USH2A</i> c.13112_13115delA AAT	p.Q4371Rfs	Het	No	LP
					<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
DTP1908095	M	37	USH2	47	<i>USH2A</i> c.4821G>C	p.Trp1607Cys	Het	No	LP
					<i>USH2A</i> c.8641_8642insTATT	p.Ser2881Leufs9	Het	No	LP
DP19010259	F	41	USH2	60	<i>USH2A</i> c.4821G>C	p.Trp1607Cys	Het	No	LP
					<i>USH2A</i> c.8641_8642insTATT	p.Ser2881Leufs9	Het	No	LP

DP19003141	M	30	RP	20	<i>USH2A</i> c.100_101insT	p.Arg34Leufs*41	Het	Yes	P
					<i>USH2A</i> c.9259G>A	p.Val3087Ile	Het	Yes	P
RD181026A	M	32	USH2	50	<i>USH2A</i> c.9469C>T	p.Gln3157*	Het	Yes	P
					<i>USH2A</i> c.9570+1G>A	-	Het	Yes	P
DTP1901236	F	34	RP	20	<i>USH2A</i> c.15562A>G	p.Ser5188Gly	Het	Yes	LP
					<i>USH2A</i> c.9340C>T	p.Pro3114Ser	Het	Yes	LP
DTP190955	M	34	USH2	41	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
					<i>USH2A</i> c.7300+1G>T	-	Het	No	P
DTP191161	M	40	RP	20	<i>USH2A</i> c.14404T>C	p.Ser4802Pro	Het	No	VUS
					<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P
DT19001417	F	9	USH2	42	<i>USH2A</i> c.99_100insT	p.Ser33Serfs42	Hom	Yes	P
DT19001018	F	20	USH2	43	<i>USH2A</i> c.4517_4518delCT	p.Arg1505Serfs*7	Het	Yes	P
					<i>USH2A</i> c.8232G>C	p.Trp2744Cys	Het	Yes	P
RD1809822A	F	28	USH2	50	<i>USH2A</i> c.8559-2A>G	-	Het	Yes	P

F: female; M: male; Het:heterozygous; Hom:homozygous; P:pathogenic; LP:likely pathogenic; VUS:variants of uncertain significance; dBHL:unit of hearing outcomes (right ear).